Current role of glucosamine in the treatment of osteoarthritis

[en] Objectives. To evaluate the interest of using the various preparations of glucosamine for symptomatic and structural management of osteoarthritis (OA). Methods. A critical analysis of the literature based on an exhaustive search (Medline, PubMed and manual search within the bibliography of retrieved manuscripts) from 1980 to 2005. Results. Despite multiple controlled clinical trials of the use of glucosamine in OA (mainly of the knee), controversy on efficacy related to symptomatic improvement continues. Differences in results originate from the differences in products, study design and study populations. Symptomatic efficacy described in multiple studies performed with glucosamine sulphate (GS) support continued consideration in the OA therapeutic armamentarium. The most compelling evidence of a potential for inhibiting the progression of OA is also obtain with GS. Conclusions. GS has shown positive effects on symptomatic and structural outcomes of knee OA. These results should not be extrapolated to other glucosamine salts [hydrochloride or preparations (over-the-counter or food supplements)] in which no warranty exists about content, pharmacokinetics and pharmacodynamics of the tablets.

Disciplines :

Rheumatology

Author, co-author :

Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique

Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique

NEUPREZ, Audrey ; Université de Liège - ULiège > Département des Sciences de la Santé Publique > Epidémiologie et santé publique

Language :

English

Title :

Current role of glucosamine in the treatment of osteoarthritis

Publication date :

May 2007

Journal title :

Rheumatology

ISSN :

1462-0324

eISSN :

1462-0332

Publisher :

Oxford Univ Press, Oxford, United Kingdom

Volume :

Issue :

Pages :

731-735

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

http://rheumatology.oxfordjournals.org/

Available on ORBi :

since 26 August 2009

Statistics

Number of views

44 (8 by ULiège)

Number of downloads

4 (4 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

van Saase JL, van Romunde LK, Cats A, Vandenbroucke JP, Valkenburg HA. Epidemiology of osteoarthritis: Zoetermeer survey. Comparison of radiological osteoarthritis in a Dutch population with that in 10 other populations. Ann Rheum Dis 1989;48:271-80.
Carmona L, Ballina J, Gabriel R, Laffon A. EPISER Study Group. The burden of musculoskeletal diseases in the general population of Spain: results from a national survey. Ann Rheum Dis 2001;60:1040-5.
Le Pen C, Reygrobellet C, Gerentes I. Financial cost of osteoarthritis in France. The "COART" France Study. Joint Bone Spine 2005;72:567-70.
Lawrence RC, Helmick GG, Arnett FC et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99.
Bolen J, Helmick CG, Sacks JJ, Langmaid G. Prevalence of self-reported arthritis or chronic joint symptoms among adults-United States, 2001. MMWR Morb Mortal Wkly Rep 2002;51:948-50.
Setnikar I, Cereda R, Pacine MA, Revel L. Antireactive properties of glucosamine sulfate. Arzneimittelforschung 1991;41:157-61.
Reginster JY, Bruyere O, Fraikin G, Henrotin Y. Current concepts in the therapeutic management of osteoarthritis with glucosamine. Bull Hosp Joint Dis 2005;63:31-6.
Largo R, Alvarez-Soria MA, Diaz-Ortego J et al. Glucosamine inhibits IL-1 beta-induced NFkappaB activation in human osteoarthritic chondrocytes. Osteoerthritis Cartilage 2003;11:290-8.
Alvarez-Soria MA, Largo R, Calvo E, Edigo J, Herrer-Beaumont G. Differential anticatabolic profile of glucosamine sulfate versus other anti-osteoarthritic drugs on human osteoarthritic chondrocytes and synovial fibroblasts in culture. Osteoarthritis Cartilage 2005;13:S153.
van Osch G, Uitterlinder EJ, Koevoet WLM, DeGroot J, Vefhaar JAN, Weinans H. Glucosamine decreases expression of anabolic and catabolic genes in human osteoarthritic cartilage explants. Osteoarthritis Cartilage 2006;14:250-7.
Altman RD, Abramson S, Bruyere O et al. Commentary: Osteoarthritis of the knee and glucosamine. Osteoarthritis Cartilage 2006;14:963-6.
Reichelt A, Förster KK, Fischer M, Rovati LC, Setnikar I. Efficacy and safety of intramuscular glucosamine sulfate in osteoarthrites of the knee. Arzneim-Forsch/Drug Res 1994;44:75-80.
Setnikar I, Palumbo R, Canali S, Zanolo G. Pharmacokinetics of glucosamine in man. Arzneim-Forsch/Drug Res 1993;43:1109-13.
Noack W, Fischer M, Förster KK, Rovati LC, Setnikar I. Glucosamine sulfate in osteoarthritis of the knee. Osteoarthritis Cartilage 1994;2:51-9.
Leffler CT, Philippi AF, Leffler SG, Mosure JC, Kim PD. Glucosamine, chodroitin, and manganese ascorbate for degenerative joint disease of the knee or low back: A randomized, double-blind, placebo-controlled pilot study. Mil Med 1999;164:85-91.
Rovati LC. Clinical development of glucosamine sulfate as selective drug in osteoarthritis. Rheumatol Europe 1997;26:70.
Houpt JB, McMillan R, Wein C, Paget-Dellio SD. Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee. J Rheumatol 1999;26:2423-30.
Rovati LC. Clinical efficacy of glucosamine sulfate in osteoarthritis of the spine. Rev Esp Rheumatol 1993;20(S1):325.
Muller-Fassbender H, Bach GL, Haase W, Rovati LC, Setnikar I. Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee. Osteoarthritis Cartilage 1994;2:61-9.
Qiu GX, Gao SN, Giacovelli G, Rovati L, Setnikar I. Efficacy and safety of glucosamine sulfate versus ibuprofen in patients with knee osteoarthritis. Arzneim-Forsch/Drug Res 1998;48:469-74.
Rovati LC. The clinical profile of glucosamine sulfate as a selective symptom modifying drug in osteoarthritis: Current data and perspectives. Osteoarthritis Cartilage 1997;5(SA):72.
Thie NMR, Prasad NG, Major PW. Evaluation of glucosamine sulfate compared to ibuprofen for the treatment of temporomandibular joint osteoarthritis: A randomized double blind controlled 3 month clinical trial. J Rheum 2001;28:1347-55.
Cohen M, Wolfe R, Mai T, Lewis D, A randomized, double blind, placebo controlled trial of a topical cream caintaining glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee. J Rheum 2003;30:523-8.
Hughes R, Carr A. a randomized, double-blind, placebo-controlled trial of glucosamine sulphate as an analgesic in osteoarthritis of the knee. Rheumatology 2002;41:279-84.
Rindone JP, Hiller D, Collacott E, Nordhaugen N, Arriola G. Randomized, controlled trial of glucosamine for treating osteoarthritis of the knee. West J Med 2000;172:91-4.
McAlindon T. Why are clinical trials of glucosamine no longer uniformly positive? Rheum Dis Clin N Am 2003;29:789-801.
Zeisel SH. Regulation of "neutraceuticals". Science 1999;285:1853-5.
McAlindon T, Formica M, LaValley M, Lehmer M, Kabbara K. Effectiveness of glucosamine for symptoms of knee osteoarthritis: Results from an Internet-based randomized double-blind controlled trial. Am J Med 2004;117:643-9.
Leeb BF, Schweitzer H, Montag K, Smolen JS. A meta-analysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol 2000;27:205-11.
McAlindon TE, LaValley MP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: A systematic quality assessment and meta-analysis. JAMA 2000;283:1469-75.
Richy F, Bruyere O, Ethgen O, Cucherat M, Henrotin Y, Reginster JY. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis. Arch Intern Mad 2003;163:1514-22.
Towhead TE, Anastassiades TP. Glucosamine therapy for osteoarthritis. J Rheumatol 1999;26;2294-7.
Pavelka K, Getterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis. Arch Int Med 2002;162:2113-23.
Bruyère O, Honore A, Rovati LC et al. Radiologic features poorly predict clinical outcomes in knee osteoarthritis. Scand J Rheumatol 2002;31:13-6.
Towheed TE, Maxwell L, Anastassiades TP et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2006 (4): Accession Number 0075320100000000-01942.
Clegg DO, Reda DJ, Harris CL et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006;354:795-808.
Herrero-Beaumont G, Ivorra JAR et al. Glucosamine sulfate in knee osteoarthritis symptoms: A randomised, double-blind, placebo-cordroled study using acetaminophen as a side comparator. Arthritis Rheum in press.
Russell AS, Aghazadeh-Habashi A, Jamali F. Active ingredient consistency of commercially available glucosamine sulfate products. J Rheumatol 2002;29:2407-9.
Hoffer LJ, Kaplan LN, Hamadeh MJ, Grigoriu AC, Baron M. Sulfate could mediate the therapeutic effect of glucosamine sulfate. Metabolism 2001;50:767-70.
Cordoba F, Nimni ME. Chondroitin sulfate and other sulfate containing chondroprotective agents may exhibit their effects by overcoming a deficiency of sulfur amino acids. Osteoarthritis Cartilage 2003;11:228-30.
Laverty S, Sandy JD, Celeste C, Vachon P, Marier JF, Plaas AH. Synovial fluid levels and serum pharmacokinetics in a large animal model following treatment with oral glucosamine at clinically relevant doses. Arthritis Rheum 2005;52:181-91.
Pham T, van der Heijde D, Altman RD et al. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage 2004;12:389-99.
Reginster JY, Deroisy R, Rovati LC. Long-term effects of glucosamine sulphate on osteoarthritis progression: A randomized, placebo-controlled clinical trial. Lancet 2001;357:251-6.
Bruyère O, Honors A, Ethgen O et al. Correlation between radiographic severity of knee osteoarthritis and future disease progression: Results from a 3-year prospective, placebo-controlled study evaluating the effect of glucosamine sulfate. Osteoarthritis Cartilage 2003;11:1-5.
Christgau S, Henrotin Y, Tanko LB et al. Osteoarthritic patients with high cartilage turnover show increased responsiveness to the cartilage protecting effects of glucosamine sulphate. Clin Exp Rheum 2004;22:36-42.
Mazzuca SA, Brandt KD, Lane KA, Katz BP. Knee pain reduces joint space width in conventional standing anteroposterior radiographs of osteoarthritic knees. Arthritis Rheum 2002;46:1223-7.
Pavelka K, Bruyere O, Rovati LC, Olejarova M, Giacovelli G, Reginster J-Y. Relief in mild-to-moderate pain is not a confounder in joint space narrowing assessment of full extension knee radiographs in recent osteoarthritis structure-modifying drug trials. Osteoarthritis Cartilage 2003;11:730-7.
Altman RD, Abadie E, Avouac B et al. Total joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis. Osteoarthritis Cartilage 2005;13:13-9.
Tapedinhas MJ, Rivera IC, Bignamini AA. Oral glucosamine sulphate in the management of arthrosis; report on a multi-centre open investigation in Portugal. Pharmacotherapeutica 1982;3:157-68.
Adams ME. Hype about glucosamine. Lancet 1999;354:353-4.
Rovati LC, Annefeld M, Giacovelli G, Schmid K, Setnikar I. Glucosamine in osteoarthritis. Lancet 1999;354:1640.
AbdelFattah W, Hammad T. Chondroitin sulfate and glucosamine: A review to their safety profile. JAMA 2001;3:17-24.
Matheson AJ, Perry CM. Glucosamine. A review of its use in the management of osteoarthritis. Drugs Aging 2003;20:1041-60.
Tannis AJ, Barban J, Conquer JA. Effect of glucosamine supplementation on fasting and non-fasting plasma glucose and serum insulin concentrations in healthy individuals. Osteoarthritis Cartilage 2004;12:506-11.